Stockholders' Equity - Additional Information (Detail)									12 Months Ended
	Jun. 07, 2017 USD ($) Tranche shares	Sep. 28, 2016 USD ($)	Sep. 23, 2016 USD ($) $ / shares shares	Jul. 05, 2016 USD ($)	Jun. 07, 2016 USD ($) Tranche shares	Apr. 04, 2015 USD ($) shares	Nov. 15, 2013 shares	Apr. 04, 2013 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($) shares	Jul. 22, 2015 $ / shares shares
Stockholders Equity [Line Items]
Business acquisition, purchase of number of shares							33,441
Proceeds from preferred stock issuable | $									$ 3,000,000
Preferred stock converted into common stock									5,154,674	3,468,804
Common stock, shares outstanding									13,723,544	13,187,544
Common stock, shares outstanding after hypothetical conversion									18,878,218
Fair value of preferred stock recorded as deemed dividend in statement of operations | $									$ 782,879	$ 627,705
Number of tranches | Tranche					2
Pineworld Capital Limited [Member]
Stockholders Equity [Line Items]
Number of tranches | Tranche	2
Anti-dilution protection of equity interest	15.00%
Anti-dilution protection of post-money valuation | $	$ 20,000,000
Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Stockholders Equity [Line Items]
Common stock, shares outstanding									13,723,544
Increase in common stock outstanding, percentage									37.60%
Fair value of preferred stock recorded as deemed dividend in statement of operations | $			$ 782,879
Series A Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized									40,000,000	40,000,000
Series A Convertible Preferred stock, shares outstanding									928	1,041
Series A Convertible Preferred Stock [Member] | Initial Tranche [Member]
Stockholders Equity [Line Items]
Proceeds from preferred stock issuable | $				$ 1,000,000
Series A Convertible Preferred Stock [Member] | Second Tranche [Member]
Stockholders Equity [Line Items]
Proceeds from preferred stock issuable | $		$ 2,000,000
Series A Convertible Preferred Stock [Member] | Angionetics Inc. [Member]
Stockholders Equity [Line Items]
Proceeds from preferred stock issuable | $		$ 2,000,000		$ 1,000,000
Preferred stock conversion basis									The Shares are initially convertible on a one to one basis into Angionetics common stock.
Percentage of stock convertible at pro rata basis	15.00%
Series A Convertible Preferred Stock [Member] | Pineworld Capital Limited [Member] | Initial Tranche [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized	200,000
Proceeds from preferred stock issuable | $	$ 1,000,000
Series A Convertible Preferred Stock [Member] | Pineworld Capital Limited [Member] | Second Tranche [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized	400,000
Proceeds from preferred stock issuable | $	$ 2,000,000
Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Stockholders Equity [Line Items]
Effective conversion price per share | $ / shares			$ 0.18					$ 0.64			$ 0.30
Series A Convertible Preferred stock, shares outstanding			1,000								1,176
Stated value per share for redemption | $ / shares			$ 1,000
Preferred stock, redemption terms									The Exchange and Redemption Agreement granted Taxus Cardium a right to redeem any or all of the outstanding Preferred Stock for its Stated Value (approximately $1,000 per share) at any time after the date of the Agreement until November 29, 2016.
Preferred stock redemption expiry date			Nov. 29, 2016
Preferred stock converted into common stock			5,554,667						5,154,674
Additional preferred stock converted into common stock			2,221,867
Share Purchase Agreement [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Percentage of common stock issued and outstanding								10.00%
Share Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member] | Angionetics Inc. [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized					600,000
Proceeds from preferred stock issuable | $					$ 3,000,000
Share Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member] | Pineworld Capital Limited [Member] | Angionetics Inc. [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized	600,000
Proceeds from preferred stock issuable | $	$ 3,000,000
Share Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Stockholders Equity [Line Items]
Series A Convertible Preferred stock, shares authorized								4,012
Proceeds from preferred stock issuable | $								$ 4,000,000
Effective conversion price per share | $ / shares								$ 0.6437
Shenzhen Qianhai Taxus [Member]
Stockholders Equity [Line Items]
Business acquisition, date of agreement									Apr. 04, 2015
Business acquisition, purchase of number of shares						600,000
Business acquisition, purchase price | $						$ 3,000,000
Payment for business acquisition | $						$ 600,000